| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_599b7149dedc397420f2bfade2f6c17c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1658 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate |
2020-12-04^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c30c22986aa131f01317f2c8f7bece1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbd87d8d28c14ee654d3fbc5e1e62241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0e15c045d6cd32a0eb2526a7d7d0d9a |
| publicationDate |
2022-08-19^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114929201-A |
| titleOfInvention |
Co-amorphous forms of beta-lactoglobulin and drugs |
| abstract |
The present invention relates to co-amorphous forms of drug substances and proteins, more particularly beta-lactoglobulin, wherein the purity of beta-lactoglobulin is at least 92% (w/w) of the total amount of protein contained in the co-amorphous form ). The present invention also relates to compositions comprising co-amorphous forms, such as pharmaceutical compositions. |
| priorityDate |
2019-12-05^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |